Delivery Order SPE2DR25D3101-SPE2DR26F5P79
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $9,879.12 by the Defense Logistics Agency on October 28, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. The contract is a firm fixed price delivery order with an ultimate completion date of November 19, 2025, and was competitively awarded with no set-aside designation. This delivery order is a child contract issued under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $2,343.59 on July 21, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This competitively awarded, firm fixed-price contract is scheduled for completion by August 11, 2025, with performance taking place at the company's Conshohocken facility. The contract was funded by the Defense Logistics Agency's Medical Supply Chain division to...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a competitive delivery order valued at $46,871.80 by the Defense Logistics Agency on September 19, 2025. The contract calls for the supply of Tezspire 210 mg/1.91 mL pen injectors and is expected to be completed by October 10, 2025. This is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's capability to compete successfully in open...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a competitively awarded delivery order from the Defense Logistics Agency valued at $4,687.18 for Tezspire 210 mg/1.91 mL pen injectors. The contract, issued on April 25, 2025, with an ultimate completion date of May 16, 2025, represents a firm fixed-price delivery order under no set-aside designation. This delivery order is issued against AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $14,818.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Tezspire 210 mg/1.91 mL pen injectables on November 12, 2025, with completion targeted for December 4, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was competitively awarded with no set-aside designation and reflects...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $2,343.59 by the Defense Logistics Agency (DLA) on September 15, 2025, for the supply of Tezspire 210 mg/1.91 mL pen units. The order is set to be completed by October 6, 2025, and will be fulfilled from the company's corporate office location in Conshohocken, Pennsylvania. This is a firm fixed-price delivery order with no set-aside designation, awarded through competitive procurement processes. This delivery order is issued...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency (DLA) on April 24, 2025, for the supply of Tezspire 210 mg/1.91 mL pen injectors. This firm fixed-price delivery order, which carries an ultimate completion date of May 15, 2025, represents a competitive award with no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This award is a child...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency's Medical Supply Chain on July 23, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This firm fixed-price, competitively awarded contract (without set-aside designation) is scheduled for completion by August 13, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on April 24, 2025, for TEZSPIRE 210 MG/1.91 ML pen auto-injectors. The delivery order, valued at $2,343.59 with a firm fixed price structure, represents a non-set-aside competitive award requiring completion by May 15, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $9,374.36 by the Defense Logistics Agency (DLA) on August 27, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectors. This is a firm fixed price, competitively awarded contract with no set-aside designation and a completion date of September 18, 2025. The award supports the company's role as a critical pharmaceutical distributor within the federal medical supply chain, with performance originating from the vendor's...
- SPE2DR25D3101Indefinite Delivery Contract
- SPE2DR25D3101-SPE2DR26F5P79Delivery Order
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency (DLA) on November 25, 2025, for the supply of Tezspire 210 mg/1.91 ml pen injectables. This firm fixed price delivery order, valued at $4,939.58, is scheduled for completion by December 17, 2025, with performance taking place at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order is issued under AmerisourceBergen's significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through December 2026. The parent IDC enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies supporting military healthcare systems and other federal customers, including the Defense Health Agency and U.S. Coast Guard. Tezspire, a biologic medication used in asthma treatment, represents one of the specialized pharmaceutical products the contractor regularly delivers through this framework agreement to support federal medical supply requirements worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.9k | 11/24/25 |